Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 9.8After-hours26.09.09 06:13S-8Offering#●●●
Apnimed, Inc.
Apnimed has adopted the '2026 Inducement Plan' and registered 2,500,000 shares of common stock to be issued under the plan. These shares will be used for equity-based awards, including stock options and restricted stock units (RSUs), to attract new officers and employees without requiring stockholder approval under Nasdaq Listing Rule 5635(c)(4).…more
$19.36+1.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.8After-hours26.09.09 06:1210-QEarnings
Apnimed, Inc.
분기 실적 보고서 제출 — 분기별 매출·손익·현금흐름이 공개되었습니다.
$19.36+1.26%vs prev closeView filingShare - 9.8After-hours26.09.09 06:108-KKey event
Apnimed, Inc.
Apnimed announced its Q2 2026 financial results and confirmed that the FDA has accepted the NDA for its OSA treatment, AD109 (Oxnimbi), with a PDUFA target date of February 28, 2027. The company also strengthened its balance sheet by completing an upsized IPO of 13.8 million shares at $16.00 per share, raising $220.8 million in gross proceeds.…more
$19.36+1.26%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12After-hours26.10.13 05:05#●●●#●●●
Apnimed to Present Phase 3 Data for OSA Candidate AD109 at CHEST 2026
Apnimed will present five abstracts, including Phase 3 trial data for its obstructive sleep apnea drug candidate AD109, at the CHEST 2026 annual meeting. The company is currently awaiting an FDA regulatory decision on the drug, with a target action date set for February 2027.…more
$19.36+1.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.2After-hours26.10.03 05:05
●●●●●●●● ●●●●● ●●●●●●
Apnimed has granted stock options for a total of 481,300 shares to 19 new employees under Nasdaq Listing Rule 5635(c)(4). This is a standard compensation practice for talent acquisition and does not have a direct material impact on the company's financials.…more
$19.36+1.26%vs prev close - 9.8After-hours26.09.09 05:41
●●●●●●●● ●●●●● ●●●●●●
Apnimed reported second-quarter earnings of $3.91 per share, significantly beating the analyst consensus estimate of -$0.34. The company also posted quarterly sales of $12.08 million.…more
$19.36+1.26%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report